Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to determine the antitumor efficacy and safety of bendamustine (SyB L-0501: 90 mg/m^2/day) for a maximum of 6 cycles (1 cycle: intravenous administration for 2 consecutive days and 26-day observation period) in patients with relapsed/refractory multiple myeloma.


Clinical Trial Description

n/a


Study Design

Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT01849848
Study type Interventional
Source SymBio Pharmaceuticals
Contact
Status Completed
Phase Phase 2
Start date November 2011
Completion date July 2013

See also
  Status Clinical Trial Phase
Recruiting NCT05427812 - Phase 1/2 Study of ISB 1442 in Relapsed/Refractory Multiple Myeloma Phase 1/Phase 2
Active, not recruiting NCT04093596 - Safety and Efficacy of ALLO-715 BCMA Allogenic CAR T Cells in in Adults With Relapsed or Refractory Multiple Myeloma (UNIVERSAL) Phase 1
Not yet recruiting NCT05498545 - Universal BCMA-targeted LUCAR-B68 Cells in Patients With Relapsed/Refractory Multiple Myeloma Phase 1
Recruiting NCT04973605 - A Phase 1b/2 Study of BGB-11417in Monotherapy and in Various Combinations With Dexamethasone and Carfilzomib in Multiple Myeloma Phase 1/Phase 2
Recruiting NCT05376345 - BCMA-targeted LCAR-BCDR Cells in Patients With Relapsed/Refractory Multiple Myeloma Phase 1
Withdrawn NCT05980507 - An Open Label, Single-arm Clinical Study Evaluating the Safety and Efficacy of ICI201 Infusion in Relapsed/Refractory Multiple Myeloma Phase 1
Active, not recruiting NCT04601935 - A Single-center Exploratory Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of a BCMA-targeted Universal LCAR-BCX Cells in Patients With Relapsed/Refractory Multiple Myeloma Phase 1
Terminated NCT06160609 - Platform Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With aOX40 (GSK3174998) in Participants With RRMM Phase 1/Phase 2
Recruiting NCT03309111 - Study of ISB 1342, a CD38/CD3 Bispecific Antibody, in Subjects With Previously Treated Multiple Myeloma Phase 1
Recruiting NCT06049290 - A Phase I/II Clinical Trial of LBL-034 in Patients With Relapsed Refractory Multiple Myeloma Phase 1/Phase 2
Recruiting NCT05259839 - A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-383 in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed/Refractory Multiple Myeloma Phase 1
Terminated NCT03318861 - Study to Evaluate the Safety and Efficacy of KITE-585 in Participants With Relapsed/Refractory Multiple Myeloma Phase 1
Active, not recruiting NCT03590652 - Daratumumab, Ixazomib, Pomalidomide, and Dexamethasone as Salvage Therapy in Relapsed/Refractory Multiple Myeloma Phase 2
Completed NCT01794520 - Study Evaluating ABT-199 in Participants With Relapsed or Refractory Multiple Myeloma Phase 1/Phase 2
Terminated NCT04142619 - Study Evaluating Safety and Efficacy of UCART Targeting CS1 in Patients With Relapsed/Refractory Multiple Myeloma (MELANI-01) Phase 1
Completed NCT01794507 - A Study Evaluating ABT-199 in Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as Standard Therapy Phase 1
Active, not recruiting NCT05160584 - A Study of Real-Life Current Standards of Care in Participants With Relapsed and/or Refractory Multiple Myeloma
Terminated NCT03287908 - A Study to Assess AMG 701 Montherapy, or in Combination With Pomalidomide, With or Without, Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma Phase 1
Completed NCT03489525 - MEDI2228 in Subjects With Relapsed/Refractory Multiple Myeloma Phase 1
Active, not recruiting NCT04309981 - Clinical Trial Using Humanized CART Directed Against BCMA (ARI0002h) in Patients With Relapsed/Refractory Multiple Myeloma to Proteasome Inhibitors, Immunomodulators and Anti-CD38 Antibody. Phase 1/Phase 2